Chimeric Therapeutics is trading 14.29% down at A$0.01, most likely reflecting unexplained selling and low-liquidity trading rather than a confirmed catalyst.
- No fresh company announcement was identified for September 15 or September 16, 2026.
- The latest major clinical update was the August 19 halt to enrolment and dosing after a second dose-limiting toxicity; that news is not new enough to establish today’s cause.